SNPSSynopsys Inc.
- Next report
- Dec 8
- Tuesday, in 26 days · after the market closes
- EPS expected
- $3.09
- quarter ending Oct 31, 2026
- Last result
- $0.09Missed
- vs $2.24 expected on May 27
- Stock move on it
- −8.61%
- one session
- Price
- $462.65
- +0.11% today · $85.0B cap
Past and upcoming reports
2
| Dec 8, 2026 | Oct 31, 2026 | After the market closes | $3.09 | not yet | |
| May 27, 2026 | Apr 30, 2026 | After the market closes | $2.24 | Missed$0.09 | −8.61% |
Pre-earnings read
No pre-earnings read for this report
None for this company right now.
After the report
May 27, 2026 report
Synopsys misses Q2 EPS by 73%, shares dip slightly amid mixed growth signals
Synopsys reported Q2 EPS of $0.09 versus $0.33 expected, a 72.8% miss, with shares down 0.9% post-earnings. Despite strong 39.6% revenue growth, EPS declined 69% year-over-year. The stock trades below key moving averages with a high P/E of 107.5, reflecting rich valuation. Analysts remain buy-tilted with a $566.7 target, implying 24% upside. Investors should watch next quarter's EPS growth and margin trends for signs of sustainable recovery.
Reported against expected
MissedReported EPS of $0.09 missed consensus estimate of $0.33 by 72.8%.
Guidance
No explicit guidance provided. mixed signals from strong revenue growth (+39.6%) but weak EPS growth (-69%).
How the stock reacted
Shares declined 0.9% on earnings day, trading below 50- and 200-day SMAs, reflecting cautious sentiment.
What changed
EPS missed by 72.8% at $0.09. revenue grew 39.6% YoY. shares down 0.9%.
What the price now assumes
Market prices cautious outlook with slight share decline and trading below key moving averages.
What it means for the business
Maintain neutral bias. monitor next quarter EPS and margin trends for recovery signals.
The next one to three months, as we saw it then
Better case25%
EPS growth rebounds with margin improvement, validating strategic AI-driven growth thesis.
Base case50%
Revenue growth remains strong but EPS recovery is gradual, keeping valuation supported but cautious.
Worse case25%
EPS and margin deterioration continue, pressuring shares amid high valuation and weak profitability.
If you hold it
Hold unless next-quarter revenue misses guidance materially or customer concentration risk worsens.
If you are watching
Add only if next-quarter guidance is reiterated or raised. avoid if guidance is cut or geopolitical risk escalates.
Scenario odds are a judgement, not measured.